Scientists from Cold Spring Harbor Laboratories have adapted the CRISPR/Cas9 gene editing technique in a way that enabled them to comprehensively search for cancer drug targets, by targeting CRISPR to specific protein-coding domains rather than the 5-prime exons of genes.